| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTRC |
| Uniprot No | Q9Y297 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-605aa |
| 氨基酸序列 | MDPAEAVLQE KALKFMCSMP RSLWLGCSSL ADSMPSLRCL YNPGTGALTA FQNSSEREDC NNGEPPRKII PEKNSLRQTY NSCARLCLNQ ETVCLASTAM KTENCVAKTK LANGTSSMIV PKQRKLSASY EKEKELCVKY FEQWSESDQV EFVEHLISQM CHYQHGHINS YLKPMLQRDF ITALPARGLD HIAENILSYL DAKSLCAAEL VCKEWYRVTS DGMLWKKLIE RMVRTDSLWR GLAERRGWGQ YLFKNKPPDG NAPPNSFYRA LYPKIIQDIE TIESNWRCGR HSLQRIHCRS ETSKGVYCLQ YDDQKIVSGL RDNTIKIWDK NTLECKRILT GHTGSVLCLQ YDERVIITGS SDSTVRVWDV NTGEMLNTLI HHCEAVLHLR FNNGMMVTCS KDRSIAVWDM ASPTDITLRR VLVGHRAAVN VVDFDDKYIV SASGDRTIKV WNTSTCEFVR TLNGHKRGIA CLQYRDRLVV SGSSDNTIRL WDIECGACLR VLEGHEELVR CIRFDNKRIV SGAYDGKIKV WDLVAALDPR APAGTLCLRT LVEHSGRVFR LQFDEFQIVS SSHDDTILIW DFLNDPAAQA EPPRSPSRTY TYISR |
| 分子量 | 68.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BTRC的3篇代表性文献摘要：
1. **《SCFβ-TrCP介导的IκBα泛素化在NF-κB激活中的作用》**(作者：Yaron et al., 1998)
摘要：该研究首次阐明BTRC(β-TrCP1)作为SCF E3泛素连接酶复合物的适配蛋白，通过识别磷酸化IκBα并介导其泛素化降解，从而激活NF-κB信号通路，在炎症和免疫反应中起关键作用。
2. **《β-TrCP通过调控Snail1泛素化促进上皮-间质转化和肿瘤转移》**(作者：Zhou et al., 2004)
摘要：研究表明BTRC通过靶向降解转录因子Snail1.调节上皮-间质转化(EMT)，影响肿瘤细胞的侵袭与转移。该机制为癌症治疗的潜在靶点提供了理论依据。
3. **《SCFβ-TrCP对tau蛋白的异常泛素化在阿尔茨海默病中的病理作用》**(作者：Hershko et al., 2006)
摘要：本文发现BTRC在阿尔茨海默病患者脑组织中介导tau蛋白异常泛素化，导致其错误折叠和聚集，提示BTRC功能失调可能与神经退行性疾病相关。
BTRC (Beta-Transducin Repeat-Containing Protein 1A), also known as β-TrCP, is an F-box protein that serves as a substrate recognition component of the Skp1-Cullin1-F-box (SCF) E3 ubiquitin ligase complex. It plays a critical role in the ubiquitin-proteasome system by targeting specific proteins for degradation, thereby regulating diverse cellular processes. The protein contains two key functional domains: an N-terminal F-box domain, which mediates interaction with Skp1 and Cullin1 in the SCF complex, and C-terminal WD40 repeats that recognize phosphorylated degradation motifs (degrons) on substrates.
BTRC is involved in numerous signaling pathways, including NF-κB activation (via IκB degradation), Wnt/β-catenin signaling (via β-catenin destruction), and DNA damage responses. It regulates cell cycle progression, apoptosis, and immune responses. Dysregulation of BTRC has been linked to cancer, neurodegenerative diseases, and inflammatory disorders. For instance, aberrant BTRC activity can promote tumorigenesis by destabilizing tumor suppressors or activating oncogenic pathways. Conversely, its inhibition may contribute to neurodegenerative conditions through protein aggregation.
Research on BTRC focuses on its therapeutic potential, as modulating its activity could restore protein homeostasis in disease states. Its dual role in cancer—acting as oncogene or tumor suppressor depending on context—highlights the complexity of targeting BTRC clinically. Structural studies of its substrate-binding mechanisms continue to inform drug design efforts.
×
